Generic Pharmaceutical Manufacturing in the US
The Generic Pharmaceutical Manufacturing industry is expanding at a steady pace, with revenue expected to increase over the five years to 2019. Increasing access to health insurance, rising total health expenditure and efforts to control prescription medication costs benefited generic manufacturers. The increasing use of generic and biosimilar products has already resulted in trillions of dollars in savings for employers, health plans, patients and the government. Increasing price scrutiny of branded prescriptions has enabled generic manufacturers to take advantage of pricing pressures and improve patient access to medicine. Over the five years to 2024, generic manufacturers are expected to lobby for policies that encourage cost savings and access to affordable medicines. Furthermore, as a growing number of patents are set to expire over the coming years, generic manufacturers are expected to have robust product pipelines. During the outlook period, generic operators are expected to explore new product lines, including biosimilars, and expand into new and emerging markets where consumers can only afford generics.
Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals. Generic drugs are produced and distributed without patent protection, and industry operators are not significantly engaged in the research and development of new drugs. The industry does not include manufacturers of nutritional supplements or cosmetic beauty products.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook